Add Yahoo as a preferred source to see more of our stories on Google. Feb 17 (Reuters) - Ocular Therapeutix said on Tuesday its experimental eye disease drug was more effective in helping patients ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Eylea HD improved vision with extended dosing intervals ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary endpoint and the only time stamp out of 10 in which the candidate was ...

Eylea and the newer Eylea HD are both injectable medications used to treat certain serious eye conditions caused by abnormal blood vessel growth or leakage. The main difference between the two ...

Bayer BAYRY announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the label extension for Eylea 8 ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...

Only a month ago, Opthea was making preparations for the potential launch of a new eye disease drug onto the market. Now, the candidate has failed to match Eylea in a phase 3 trial, leaving the ...

Earlier this month at the J.P. Morgan Healthcare Conference, Regeneron got its Eylea sales news out of the way. As has been the case for several quarters, as sales of Eylea HD have increased, those of ...

Regeneron has had its hands full this year contending with regulatory setbacks, Amgen's marketed Eylea biosimilar and Roche's hard-charging ophthalmology rival Vabysmo. Next year, the biosimilar ...

Feb 17 (Reuters) - Ocular Therapeutix said on Tuesday its experimental eye disease drug was more effective in helping patients maintain their vision compared to Regeneron's approved treatment Eylea in ...